These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 26795084)

  • 1. Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.
    Vidal-Petiot E; Rea D; Serrano F; Stehlé T; Gardin C; Rousselot P; Peraldi MN; Flamant M
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):169-74. PubMed ID: 26795084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
    Molica M; Scalzulli E; Colafigli G; Fegatelli DA; Massaro F; Latagliata R; Foà R; Breccia M
    Ann Hematol; 2018 Oct; 97(10):1803-1808. PubMed ID: 29806063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
    Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
    Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
    Akay OM; Mutlu F; Gülbaş Z
    Turk J Haematol; 2016 Jun; 33(2):127-30. PubMed ID: 26377244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients.
    Marcolino MS; Boersma E; Clementino NCD; Macedo AV; Marx-Neto AD; Silva MHCR; van Gelder T; Akkerhuis KM; Ribeiro AL
    Ann Oncol; 2011 Sep; 22(9):2073-2079. PubMed ID: 21310760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
    Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
    Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
    J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
    Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib.
    Atiq F; Broers AE; Andrews LM; Doorduijn JK; Koch BC; Van Gelder T; Versmissen J
    Eur J Clin Pharmacol; 2016 Jun; 72(6):719-23. PubMed ID: 26965514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.
    Gómez-Sámano MÁ; Baquerizo-Burgos JE; Coronel MFC; Wong-Campoverde BD; Villanueva-Martinez F; Molina-Botello D; Avila-Rojo JA; Palacios-Báez L; Cuevas-Ramos D; Gomez-Perez FJ; Zentella-Dehesa A; Aguayo-González Á; Gulias-Herrero A
    BMC Endocr Disord; 2018 Nov; 18(1):77. PubMed ID: 30390651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 13. Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.
    Clapp GD; Lepoutre T; El Cheikh R; Bernard S; Ruby J; Labussière-Wallet H; Nicolini FE; Levy D
    Cancer Res; 2015 Oct; 75(19):4053-62. PubMed ID: 26359456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
    Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
    Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.
    Sakurai M; Kikuchi T; Karigane D; Kasahara H; Matsuki E; Hashida R; Yamane Y; Abe R; Koda Y; Toyama T; Kato J; Shimizu T; Yokoyama Y; Suzuki S; Nakamura T; Okamoto S; Mori T
    Int J Hematol; 2019 Mar; 109(3):292-298. PubMed ID: 30680668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 17. First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia.
    Capron A; Antunes MV; Wagner SC; Mattevi VS; Vieira N; Leite R; Reginato F; Capra M; Fogliatto L; Wallemacq P; Linden R
    Clin Chim Acta; 2016 Jan; 453():42-7. PubMed ID: 26657979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
    Angriman F; Gutierrez Acevedo MN; Rossi MS; Gimenez Conca AD; Otero V; Arbelbide JA; Michelángelo H
    Turk J Haematol; 2015 Jun; 32(2):193-4. PubMed ID: 26316496
    [No Abstract]   [Full Text] [Related]  

  • 19. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.